Skip to Main Content

Program

Angiogenesis, Exudation, and Degeneration 2020

Saturday, February 9, 2019
Program is subject to change

7:00 am Registration and Continental Breakfast
7:50 Welcome and Overview / Pre-Program Test
Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Thomas A. Albini, MD
  Session I: Aging, Disease Pathogenesis, and Imaging
Moderators: Philip J. Rosenfeld, MD, PhD and Zohar Yehoshua, MD, MHA
8:00 Metabolic Networks and the RPE-Photoreceptor Ecosystem in Aging and Degeneration
Philip Luthert, MBBS

8:08 Ultrahigh Speed OCTA for Assessing Choricapillaris Flow Impairment
James G. Fujimoto, PhD
8:16 Challenges in Imaging the Choriocapillaris
Richard F. Spaide, MD
8:24 Choriocapillaris Quantification with Phansalkar's Local Thresholding: Do's and Don'ts
Zhongdi Chu, PhD
8:32 Choriocapillaris in Myopia
SriniVas R. Sadda, MD

8:40 Choroidal Vessel Imaging and Quantification
Ruikang (Ricky) Wang, PhD

8:48 The Choroid in AMD: Connecting the Dots
Philip J. Rosenfeld, MD, PhD

8:56 Deep Learning and Reticular Pseudodrusen
Emily Y. Chew, MD

  Session II: Retinal Diseases and Functional Endpoints
Moderators: Thomas A. Albini, MD and Jorge A. Fortun, MD
9:04 MacTel2 as a “Serine/Ceramide-Opathy”
Martin Friedlander, MD, PhD

9:12 Epidemiology of Common Retinal Diseases in Retina Practices in the United States
Andrew A. Moshfeghi, MD, MBA

9:20 Functional Imaging of Mitochondria in Retinal Diseases
Rishi P. Singh, MD

9:28 Novel Analytics to Examine Impact of Fluctuations in Retinal Thickness on Visual Outcomes
Usha Chakravarthy, MD

9:36 Drusen and Retinal Diseases
Lawrence A. Yannuzzi, MD

9:44 Integrating Microperimetry into Clinical Trials of Nonexudative AMD
Nadia Waheed, MD

9:52 Rod-and-Cone-Mediated Vision in Eyes with Hyperreflective Foci: An Outcome Measure for Oil Spill Trials?
Christine A. Curcio, PhD

10:00 Normal and Low Luminance Quantitative Contrast Sensitivity: A Novel Functional Endpoint for Rapid Measurement of Spatial Contrast Sensitivity Functions in Dry AMD
Karl G. Csaky, MD, PhD

  Session III: AMD II
Moderators: Philip J. Rosenfeld, MD, PhD and Raquel Goldhardt, MD
10:08 Retina Trends – A VC’s Perspective
Emmett T. Cunningham, Jr., MD, PhD, MPH

10:16 Update in Hemera’s Gene Therapy Programs
Jay S. Duker, MD

10:24 Kamuvudines for AMD: The Saga Continues
Jayakrishna Ambati, MD

10:32 Phase 1 Results of a Systemic Antisense Inhibitor of Complement Factor B for Geographic Atrophy
Sunil S. Patel, MD, PhD

10:40 Update on FHTR2163 (anti-HtrA1) for Dry AMD
Vrinda Hershberger, MD, PhD

10:48 Update on Elamipretide for the Treatment of AMD
Scott W. Cousins, MD

10:56 Phase 2 Study Results of Risuteganib in Dry AMD
Peter K. Kaiser, MD

11:04 Risuteganib for the Treatment of Dry AMD: Structure/Function Correlations
Glenn J. Jaffe, MD

11:12 Update on Brimonidine Intravitreal Implant for Dry AMD
Ryan Rich, MD

11:20 C3 inhibition in Geographic Atrophy
Cedric G. Francois, MD, PhD

  Session IV: AMD III
Moderators: Harry W. Flynn, Jr., MD and Luis J. Haddock, MD
11:28 PROCON Year 2 Results
Jeffrey S. Heier, MD

11:36 Non-Neovascular Exudative Age Related Macular Degeneration: How to Unmask the Masquerader
David Sarraf, MD

11:44 Update on Stem Cell Therapies for AMD
Amir H. Kashani, MD, PhD

11:52 Unregulated Stem Cells for Ocular Disease: What Happened after the NEJM Publication
Thomas A. Albini, MD

12:00pm Retinal Implants: Where Are We Now?
Jean-François Korobelnik, MD

12:08 Advanced Retinal Implants
Mark S. Humayun, MD, PhD

12:16 Lunch
  Session V: Macular Neovasculation in AMD and PCV
Moderators: Philip J. Rosenfeld, MD, PhD and Luis J. Haddock, MD
1:16 The Importance of MNV Type Classification in the Interpretation of the Results of Clinical Trials
Giovanni Staurenghi, MD

1:24 Detection of Non-Exudative Subclinical MNV in AMD from Structural OCT Scans Using Deep Learning
Aaron Y. Lee, MD

1:32 AI Based Fluid Quantification on Serial OCT Images from a Patient Self-operated Home OCT Device
Anat Loewenstein, MD

1:40 Automated Volumetric Assessment of Subclinical Non-Exudative MNV Using SS-OCTA
Luis de Sisternes, PhD

1:48 Rotational 3D OCTA
Giuseppe Querques, MD, PhD

1:56 Diagnosis of PCV Using SS-OCTA
Hiroko Terasaki, MD, PhD

2:04 Volume Rendering of OCTA in PCV
K. Bailey Freund, MD

2:12 A Comparison Study of Polypoidal Choroidal Vasculopathy Imaged with ICGA and SS-OCTA
Seung-Young Yu, MD

2:20 Longitudinal Changes in Subclinical PCV
Gemmy Cheung, MBBS, FRCOphth, FAMS, MCI

2:28 Longitudinal Observations of PCV Using SS-OCTA
Fenghua Wang, MD

  Session VI: Treatments for Neovasculation in AMD and ROP
Moderators: Thomas A. Albini, MD and Ninel Z. Gregori, MD
2:36 Immunology of Gene Therapy
Janet L. Davis, MD

2:44 Phase 1 study of Intravitreal Gene Therapy with DVM-022 for Neovascular AMD (OPTIC Trial)
David S. Boyer, MD

2:52 RGX-314 Gene Therapy for wAMD and Diabetic Retinopathy
Jeffrey S. Heier, MD

3:00 Treatment of Newly Diagnosed and Treatment Resistant Neovascular AMD with the Oral CCR3 Inhibitor ALK4290
Michael W. Stewart, MD

3:08 Results of the Phase I/II SUSHI Study of Intravitreal RBM-007 in Exudative AMD
Quan Dong Nguyen, MD, MSc

3:16 Update on Phase 1b and Phase 2 Studies of KSI-301: A Novel Anti-VEGF Antibody Biopolymer Conjugate with Potential for Extended Durability in Wet AMD
Diana V. Do, MD

3:24 Results of the Opthea OPT-302 Phase 2b Study: Combined VEGF-C / VEGF-D Suppression for nvAMD
Pravin U. Dugel, MD

3:32 Phase 2 LADDER Trial Using the Port Delivery System with Ranibizumab: End of Study, Long-term Follow-up Results
Carl D. Regillo, MD

3:40 Faricimab Update
Karl G. Csaky, MD, PhD

3:48 Brolucizumab Update
Lawrence J. Singerman, MD

3:56 Do We Need More VEGF Blockade?- The Rationale for a Clinical Trial Testing High-Dose Aflibercept
David M. Brown, MD

4:04 Update on ROP and Anti-VEGF Clinical Trials
Darius M. Moshfeghi, MD

  Session VII: Diabetes
Moderators: Harry W. Flynn, Jr. MD and Justin H. Townsend, MD
4:12 Effect of Industry Funding on Abstract Bias in the Literature for Intravitreal Pharmacotherapy for Retinal Vascular Disease
Jayanth Sridhar, MD

4:20 DRCR Retina Network Trials and Real World Experience
Jennifer Sun, MD

4:28 Diabetic Retinopathy: Is a New Classification on the Way?
Lee M. Jampol, MD

4:36 Artificial Intelligence Assisted Approaches for Diabetic Retinopathy Screening
Michael S. Ip, MD

4:44 The Pattern and Density of Retinal Capillary Plexuses from the Fovea to the Periphery Using SS-OCTA
Ramin Tadayoni, MD, PhD

4:52 Wide-field SS-OCTA is Better than FA in Detecting Capillary Dropout, Neovascularization and IRMA in Diabetic Retinopathy
Toshinori Murata, MD, PhD

5:00 Widefield SS-OCTA in Diabetic Retinopathy
Harry W. Flynn, Jr. MD

5:08 Development of DME in Fellow Eyes from VIVID/VISTA
Dilsher Dhoot, MD

5:16 Intravitreal Aflibercept for Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR): 2-Year Outcomes of the Phase 3 PANORAMA Study
Charles C. Wykoff, MD, PhD

  Session VIII: Diabetes, Uveitis, and Retinal Degenerations
Moderator: Philip J. Rosenfeld, MD, PhD and Thomas A. Albini, MD
5:24 A Novel Implant for Delivering Low-Dose Extended Release Dexamethasone for Macular Edema
Elias Reichel, MD

5:32 The Oculis OCS-01 Phase 1/2 Study: An Effective Topical Therapeutic for DME
Pravin U. Dugel, MD

5:40 Front-line Local Therapies for Uveitis: From Clinical Trials to Practice
Steven Yeh, MD

5:48 Treatments and Clinical Trials in Inherited Retinal Degenerations
Byron L. Lam, MD

5:56 Phase 2 1-year Results of the JCyte Trial for Retinitis Pigmentosa
David S. Boyer, MD

6:04 Results of a Clinical Trial Investigating N-acetylcysteine in Retinitis Pigmentosa
Peter A. Campochiaro, MD

6:12 Post-Program Test and Closing Remarks
6:20 Adjourn/Cocktail Reception